WallStreetZenWallStreetZen

NASDAQ: VRAX
Virax Biolabs Group Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VRAX stock forecasts and price targets.

Forecast return on equity

Is VRAX forecast to generate an efficient return?

Company
N/A
Industry
112.25%
Market
268.35%

Forecast return on assets

Is VRAX forecast to generate an efficient return on assets?

Company
N/A
Industry
35.42%

VRAX earnings per share forecast

What is VRAX's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.04

VRAX revenue forecast

What is VRAX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$13.8M+217,274.82%
Avg 2 year Forecast
$4.1M+64,344.8%
VRAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRAX revenue growth forecast

How is VRAX forecast to perform vs Biotechnology companies and vs the US market?

Company
2,438.6%
Industry
287.9%
Market
58.52%
VRAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRAX$0.59N/AN/A
ELAB$6.03N/AN/A
SLXN$3.30N/AN/A
MLEC$0.60N/AN/A
XRTX$0.63N/AN/A
View Top Biotech Stocks

Virax Biolabs Group Stock Forecast FAQ

What is VRAX's earnings growth forecast for 2026-2026?

(NASDAQ: VRAX) Virax Biolabs Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 39.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.26%.

Virax Biolabs Group's earnings in 2025 is -$6,061,247.

In 2026, VRAX is forecast to generate $177,152 in earnings, with the lowest earnings forecast at $170,205 and the highest earnings forecast at $182,362.

If you're new to stock investing, here's how to buy Virax Biolabs Group stock.

What is VRAX's revenue growth forecast for 2026-2027?

(NASDAQ: VRAX) Virax Biolabs Group's forecast annual revenue growth rate of 2,438.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 287.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 58.52%.

Virax Biolabs Group's revenue in 2025 is $6,331.On average, 3 Wall Street analysts forecast VRAX's revenue for 2026 to be $59,753,998, with the lowest VRAX revenue forecast at $57,409,342, and the highest VRAX revenue forecast at $61,512,491.

In 2027, VRAX is forecast to generate $17,715,180 in revenue, with the lowest revenue forecast at $17,020,468 and the highest revenue forecast at $18,236,215.

What is VRAX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: VRAX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.42%.

What is VRAX's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: VRAX) Virax Biolabs Group's current Earnings Per Share (EPS) is -$1.62. In 2026, VRAX's EPS is forecast to hit $0.04 (min: $0.04, max: $0.04).

What is VRAX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: VRAX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.